AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility measures (400-m walk time, SPPB score)
Number of subjects: 1635
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 1635
Study 24890385 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β/Smad3 tumor-suppressor signature
Number of subjects: 0
Study 24890385 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β
Number of subjects: 0
Study 24890385 — intervention group
Group type: COMPARATOR
Intervention: TGF-β antagonists
Number of subjects: 0
Study 24890823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxentan (6-week treatment)
Number of subjects: 27
Study 24890823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6-week treatment)
Number of subjects: 27
Study 24890823 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (6-week treatment)
Number of subjects: 27
Study 24890858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m² IV on d1, 4, 8, 11) and Doxorubicin (15 mg/m² IV on d1, 8) in 21-day cycles
Number of subjects: 38
Study 24890858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Doxorubicin
Number of subjects: 38
Study 24891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Third assay (sandwich ELISA) for measuring glucagon concentrations
Number of subjects: 0
Study 24891019 — intervention group
Group type: COMPARATOR
Intervention: C-terminal glucagon RIA
Number of subjects: 0
Study 24891132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 101
Study 24891132 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 101
Study 24891156 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 14
Study 24891156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 14
Study 24891156 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study 24891274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m2 iv) and Vorinostat (230 mg/m2 PO div BID) followed by chemotherapy (vincristine, prednisone, PEG-asparaginase, doxorubicin)
Number of subjects: 13
Study 24891274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 13
Study 24891274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and Vorinostat
Number of subjects: 13
Study 24891325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose hMSCs (5×10(6) hMSCs/kg)
Number of subjects: 19
Study 24891325 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose hMSCs (10×10(6) hMSCs/kg)
Number of subjects: 19
Study 24891325 — intervention group
Group type: COMPARATOR
Intervention: Control (PlasmaLyte A)
Number of subjects: 19
Study 24891429 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine/artesunate (fixed-dose combination) administered orally once daily for 3 days
Number of subjects: 48
Study 24892263 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg, maximum 25 mg/dose) twice weekly for 4 to 8 weeks
Number of subjects: 34
Study 24892263 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 34
Study 24892263 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (control)
Number of subjects: 34
Study 24892422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaplex (5% Intravenous Immunoglobulin, IVIg) at a dosage of 1 g/kg on two consecutive days
Number of subjects: 35
Study 24892422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaplex (5% Intravenous Immunoglobulin, IVIg)
Number of subjects: 35
Study 24893322 — intervention group
Group type: EXPERIMENTAL
Intervention: Blast exposure and/or mTBI (B/mTBI)
Number of subjects: 25
Study 24893322 — intervention group
Group type: COMPARATOR
Intervention: No blast exposure or mTBI (No B/mTBI)
Number of subjects: 25
Study 24893855 — intervention group
Group type: EXPERIMENTAL
Intervention: De-sialylated CD8 T cells
Number of subjects: 0
Study 24893855 — intervention group
Group type: EXPERIMENTAL
Intervention: CD103(+) CD8 T cells
Number of subjects: 0
Study 24893855 — intervention group
Group type: COMPARATOR
Intervention: Tumor ST3Gal-II expression
Number of subjects: 0
Study 24893962 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of sublingual misoprostol
Number of subjects: 481
Study 24894084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with two cycles of Epirubicin and Paclitaxel (Epi-Tax), followed by three consecutive HDCT cycles (one with Paclitaxel/Thiotepa (Thio-Tax) and two with Ifosfamide-Carboplatin-Etoposide regimen)
Number of subjects: 45
Study 24894084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 45
Study 24894668 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise intervention
Number of subjects: 470
Study 24895163 — intervention group
Group type: EXPERIMENTAL
Intervention: PESP present (ratio > 1)
Number of subjects: 941
Study 24895163 — intervention group
Group type: COMPARATOR
Intervention: PESP absent
Number of subjects: 941
Study 24895163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PESP presence and LVEF ≤ 35%
Number of subjects: 941
Study 24895163 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 941
Study 24895163 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 941
Study 24895163 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of recorded VPCs
Number of subjects: 941
Study 24898091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) IL-2
Number of subjects: 40
Study 24898305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with cisplatin (75 mg/m(2), day 1) and docetaxel (75 mg/m(2), day 2)
Number of subjects: 69
Study 24898305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with carboplatin (AUC6) and paclitaxel (200 mg/m(2), day 2)
Number of subjects: 69
Study 24898305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2))
Number of subjects: 69
Study 24898305 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/docetaxel or carboplatin/paclitaxel (standard doses)
Number of subjects: 69
Study 24898549 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7155 (anti-CSF-1R antibody)
Number of subjects: 0
Study 24898665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 24898665 — intervention group
Group type: COMPARATOR
Intervention: Tositumomab and iodine I-131 tositumomab
Number of subjects: 0
Study 24898826 — intervention group
Group type: EXPERIMENTAL
Intervention: TET2 mutations
Number of subjects: 215
Study 24898826 — intervention group
Group type: EXPERIMENTAL
Intervention: TET2 mutation status
Number of subjects: 215
Study 24899155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet weight loss intervention
Number of subjects: 78
Study 24900938 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of continuous sedative and opioid infusion
Number of subjects: 60
Study 24900938 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sedation
Number of subjects: 60
Study 24901360 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine 1000 mg/m intravenously over 100 minutes and oxaliplatin 80 mg/m intravenously over 2 hours, every 2 weeks.
Number of subjects: 38
Study 24901360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine 1000 mg/m intravenously over 30 minutes days 1, 8, and 15 every 4 weeks.
Number of subjects: 38
Study 24901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Septin9 DNA methylation based blood test (Epi proColon)
Number of subjects: 301
Study 24901436 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 301
Study 24901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of Epi proColon and FIT
Number of subjects: 301
Study 24901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi proColon test
Number of subjects: 301
Study 24901436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Epi proColon and FIT)
Number of subjects: 301
Study 24902119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerogenic medication
Number of subjects: 455
Study 24902119 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 455
Study 24902119 — intervention group
Group type: COMPARATOR
Intervention: Portal hypertension (measured by HVPG)
Number of subjects: 455
Study 24902119 — intervention group
Group type: COMPARATOR
Intervention: Liver cirrhosis (LC)
Number of subjects: 455
Study 24903064 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 61
Study 24903080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on the Ki-67 index
Number of subjects: 1848
Study 24903080 — intervention group
Group type: COMPARATOR
Intervention: CS-IHC4 + nomogram score
Number of subjects: 1848
Study 24903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 750 mg every 6 hours
Number of subjects: 51
Study 24903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 1000 mg every 8 hours
Number of subjects: 51
Study 24903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 1000 mg every 6 hours
Number of subjects: 51
Study 24903199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred care
Number of subjects: 996
Study 24903199 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in pregnancy rates
Number of subjects: 996
Study 24903202 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with recombinant FSH (rFSH)
Number of subjects: 747
Study 24903629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib 80 mg twice daily for 18 weeks
Number of subjects: 39
Study 24903795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent regimen of rifampin (RMP), pyrazinamide (PZA), and ethambutol (EMB) administered BIW or TIW for 6 months after initial daily doses.
Number of subjects: 98
Study 24903982 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1509
Study 24903982 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 1509
Study 24903982 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 1509
Study 24903982 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR with concomitant coronary artery bypass grafting
Number of subjects: 1509
Study 24903982 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident stroke
Number of subjects: 1509
Study 24903982 — intervention group
Group type: COMPARATOR
Intervention: Pre-AVR stroke rate
Number of subjects: 1509
Study 24903982 — intervention group
Group type: COMPARATOR
Intervention: Post-AVR stroke rate
Number of subjects: 1509
Study 24904120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib at maximum tolerated dose (MTD) of 2.97 mg/m(2) given weekly for 3 of 4 weeks.
Number of subjects: 60
Study 24904120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib at MTD of 2.97 mg/m(2).
Number of subjects: 60
Study 24905490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon/ribavirin therapy
Number of subjects: 0
Study 24905490 — intervention group
Group type: EXPERIMENTAL
Intervention: IL28B rs12979860 CC SNP
Number of subjects: 0
Study 24905490 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoH and IL28B CC SNP
Number of subjects: 0
Study 24905490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 0
Study 24905490 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 24905567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline stress
Number of subjects: 350
Study 24905567 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased leisure-time physical activity (LTPA) from baseline to posttest
Number of subjects: 350
Study 24905795 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum chromium everolimus-eluting stents (PtCr-EES)
Number of subjects: 196
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonovine
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2α)
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin in augmented labour
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin in non-augmented labour
Number of subjects: 46
Study 24906304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin in absence of labour
Number of subjects: 46
Study 24906361 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Fungitell assay
Number of subjects: 109
Study 24906361 — intervention group
Group type: COMPARATOR
Intervention: Culture-negative samples
Number of subjects: 109
Study 24906384 — intervention group
Group type: EXPERIMENTAL
Intervention: 124I and 18F-FDG PET/CT
Number of subjects: 100
Study 24906384 — intervention group
Group type: COMPARATOR
Intervention: 131I therapy
Number of subjects: 100
Study 24906637 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (initial dose 150 mg or 300 mg, escalating up to 600 mg every 4 weeks)
Number of subjects: 6
Study 24906637 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (at maximum dose)
Number of subjects: 6
Study 24906637 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 6
Study 24907095 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental autistic tendency measured by Autism Spectrum Quotient (AQ)
Number of subjects: 491
Study 24907095 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived family support and parental education
Number of subjects: 491
Study 24907357 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Number of subjects: 0
Study 24907357 — intervention group
Group type: COMPARATOR
Intervention: Horse antithymocyte globulin
Number of subjects: 0
Study 24907357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antithymocyte globulins
Number of subjects: 0
Study 24907633 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (neo-CRT) followed by surgery
Number of subjects: 28
Study 24907635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg) plus gemcitabine (1000 mg/m² on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 34
Study 24907635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (6, 10, or 15 mg/kg) plus gemcitabine
Number of subjects: 34
Study 24907636 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 195
Study 24907636 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF) (optimally dosed)
Number of subjects: 195
Study 24907636 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF) (suboptimally dosed)
Number of subjects: 195
Study 24907636 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 195
Study 24907636 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with booster inoculations
Number of subjects: 195
Study 24909546 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-HD-HSV1/2 PCR
Number of subjects: 36
Study 24909918 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental experiences/needs during child's end-of-life care at home
Number of subjects: 50
Study 24909918 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of paediatric end-of-life care services in the home care setting
Number of subjects: 50
Study 24909918 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through semi-structured interviews with parents
Number of subjects: 50
Study 24909918 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data about patient's characteristics from medical charts
Number of subjects: 50
Study 24909918 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for data analysis
Number of subjects: 50
Study 24911148 — intervention group
Group type: EXPERIMENTAL
Intervention: NiCord (UCB-derived cell product expanded for 21 days with nicotinamide)
Number of subjects: 11
Study 24911148 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 11
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 228
Study 24911895 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 228
Study 24911895 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 228
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvaccine serotypes
Number of subjects: 228
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 15
Number of subjects: 228
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 35B
Number of subjects: 228
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin nonsusceptible isolates
Number of subjects: 228
Study 24911895 — intervention group
Group type: COMPARATOR
Intervention: Earlier studies
Number of subjects: 228
Study 24911895 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotypes 15 and 35B
Number of subjects: 228
Study 24912106 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (open-label) for 8-14 weeks
Number of subjects: 2477
Study 24912489 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg PO daily) and Everolimus (10 mg PO daily)
Number of subjects: 55
Study 24912489 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole and Everolimus
Number of subjects: 55
Study 24912564 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV adherence > 9 h/day
Number of subjects: 213
Study 24912564 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV adherence > 5 h/day
Number of subjects: 213
Study 24912564 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV adherence
Number of subjects: 213
Study 24912564 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV use > 9 h/day
Number of subjects: 213
Study 24912660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal uptake of p-cresol (measured by 24 h urinary excretion of PCS)
Number of subjects: 200
Study 24912660 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary excretion of PCS (per 100 μmol increase)
Number of subjects: 200
Study 24912660 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of PCS (in multivariate analysis)
Number of subjects: 200
Study 24912797 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 (0.6, 18, and 180 mg, SC)
Number of subjects: 175
Study 24912797 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 (0.02-2.5 mg/kg, IV)
Number of subjects: 175
Study 24912797 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 (IV and SC)
Number of subjects: 175
Study 24912797 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 (SC)
Number of subjects: 175
Study 24913040 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item survey administered to patients
Number of subjects: 106
Study 24913040 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-item tool based on beliefs about maintenance mesalamine and concerns about side effects
Number of subjects: 106
Study 24913040 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-item tool
Number of subjects: 106
Study 24913066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (300 mg daily for a maximum of 10 weeks)
Number of subjects: 20
Study 24913066 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (not specified in the abstract)
Number of subjects: 20
Study 24913160 — intervention group
Group type: EXPERIMENTAL
Intervention: XOMA 3AB
Number of subjects: 24
Study 24913160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24913999 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet and anticoagulant therapy strategies
Number of subjects: 1134
Study 24913999 — intervention group
Group type: EXPERIMENTAL
Intervention: High and intermediate bleeding risk procedures
Number of subjects: 1134
Study 24913999 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1134
Study 24913999 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhagic complications
Number of subjects: 1134
Study 24914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 1)
Number of subjects: 16
Study 24914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 2)
Number of subjects: 16
Study 24914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/day plus Sunitinib 37.5 mg/day (cohort 3)
Number of subjects: 16
Study 24914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (MTD)
Number of subjects: 16
Study 24914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day
Number of subjects: 16
Study 24914098 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolysed rice protein infant formula (eRHF)
Number of subjects: 39
Study 24914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole and anidulafungin combination therapy
Number of subjects: 238
Study 24914120 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole monotherapy
Number of subjects: 238
Study 24914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin treatment duration
Number of subjects: 238
Study 24914492 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COPD exacerbation
Number of subjects: 44
Study 24915120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 122